Latest Headlines

  1. Mission Bio Unveils Industry-First Single-Cell Genotype And Targeted Gene Expression Solution Aimed At Derisking Cancer Drug Clinical Development 6/5/2025

    Mission Bio, a leader in single-cell multi-omics solutions for precision medicine, today announced the launch of its Single-Cell Genotype and Targeted Gene Expression assay, expanding the capabilities of its Tapestri Platform to become the only commercial solution that delivers simultaneous genotype and targeted gene expression profiling from over 10,000 single cells.

  2. Molecular Health And Axxam Enter Into A Strategic Partnership To Bolster The Discovery Of Innovative Targets In Drug Development 6/4/2025

    Axxam S.p.A., a premier provider of integrated early discovery services, and Molecular Health GmbH, a leader in artificial intelligence (AI)-driven development solutions, are announcing a strategic collaboration to accelerate the identification and validation of novel therapeutic targets across a broad range of therapeutic areas.

  3. New NIST Standard Helps Deliver The Right Dosage Of Cancer-Fighting Drugs 6/3/2025

    Scientists at the National Institute of Standards and Technology (NIST) have developed the first U.S. standard for measuring the radioactivity of actinium-225, a radioactive isotope that drug companies are using to develop a new class of anticancer drugs.

  4. Technology Developed By ANBM To Be Utilized For New Drug Discovery Program 6/3/2025

    Furthering the University of Arizona College of Medicine – Phoenix’s research mission to cultivate research both locally and globally, the Center for Applied NanoBioscience and Medicine (ANBM) has agreed to a technology development program and commercialization partnership with Mitsubishi Gas Chemical Company (MGC), Inc.

  5. Renovaro Secures Key U.S. Patent To Strengthen AI-Driven Drug Discovery And Diagnostics Platform 6/3/2025

    Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” (Application No. 18/058,752).

  6. Tenpoint Therapeutics Ltd. Announces FDA Acceptance Of New Drug Application For BRIMOCHOL PF For The Treatment Of Presbyopia 6/3/2025

    Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for BRIMOCHOL PF for the treatment of presbyopia.

  7. Orbis Medicines Accelerates Next-Generation Oral Macrocycle Platform With Enhanced Artificial Intelligence Capabilities Of Gefion Supercomputer 6/3/2025

    Orbis Medicines, a leader in oral macrocycle drug discovery, and the Danish Center for AI Innovation (DCAI) today announced that Orbis has begun using Denmark’s first AI supercomputer, Gefion, which is owned and operated by DCAI.

  8. Kivu Bioscience Selects Sterling Pharma Solutions For cGMP Manufacturing Of Lead Oncology Antibody-Drug Conjugate KIVU-107 6/2/2025

    Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates, announced today a manufacturing partnership with Sterling Pharma Solutions, a global contract development and manufacturing organisation, to produce cGMP-quality material for Phase 1 clinical trials of its lead oncology antibody-drug conjugate (ADC) candidate, KIVU-107.

  9. BioNTech And Bristol Myers Squibb Announce Global Strategic Partnership To Co-Develop And Co-Commercialize Next-Generation Bispecific Antibody Candidate BNT327 Broadly For Multiple Solid Tumor Types 6/2/2025

    BioNTech SE and Bristol Myers Squibb today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

  10. ImmunAbs Announces FDA Phase 2 IND Approval Of IM-101, A Novel Complement C5 Inhibitor, For Treatment Of Myasthenia Gravis 6/2/2025

    ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis.